Global Retirement Partners LLC boosted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 164.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,282 shares of the biotechnology company’s stock after purchasing an additional 16,972 shares during the quarter. Global Retirement Partners LLC’s holdings in Exelixis were worth $1,594,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Cassaday & Co Wealth Management LLC bought a new stake in Exelixis in the first quarter worth $27,000. Gen Wealth Partners Inc purchased a new position in Exelixis during the third quarter worth $38,000. Western Wealth Management LLC bought a new position in Exelixis during the first quarter valued at $29,000. Mather Group LLC. increased its position in Exelixis by 124.6% during the third quarter. Mather Group LLC. now owns 757 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 420 shares during the last quarter. Finally, CENTRAL TRUST Co raised its stake in shares of Exelixis by 44.9% in the third quarter. CENTRAL TRUST Co now owns 784 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 243 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on EXEL shares. Wall Street Zen upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Monday, November 9th. Zacks Research raised shares of Exelixis from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 1st. Barclays raised their price objective on shares of Exelixis from $49.00 to $54.00 and gave the stock an “equal weight” rating in a research note on Friday, October 30th. Royal Bank Of Canada boosted their target price on Exelixis from $51.00 to $58.00 and gave the company a “sector perform” rating in a research report on Friday, October 30th. Finally, Citizens Jmp increased their price target on Exelixis from $55.00 to $65.00 and gave the stock a “market outperform” rating in a report on Monday, October 19th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Exelixis currently has an average rating of “Hold” and an average target price of $58.62.
Exelixis Stock Down 1.8%
EXEL opened at $64.63 on Friday. The company has a market cap of $15.77 billion, a price-to-earnings ratio of 19.35, a PEG ratio of 1.67 and a beta of 0.45. Exelixis, Inc. has a 52-week low of $39.71 and a 52-week high of $73.69. The firm’s fifty day simple moving average is $63.20 and its two-hundred day simple moving average is $52.84.
Exelixis (NASDAQ:EXEL – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.05. The business had revenue of $658.70 million during the quarter, compared to analyst estimates of $646.51 million. Exelixis had a return on equity of 45.54% and a net margin of 35.45%. The business’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.78 earnings per share. On average, research analysts forecast that Exelixis, Inc. will post 3.42 EPS for the current year.
Exelixis Company Profile
Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer.
Read More
- Five stocks we like better than Exelixis
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
